+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Effects of Etidronate and Lovastatin on the Regression of Atherosclerosis in Cholesterol-Fed Rabbits


      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Eighty New Zealand rabbits in eight groups (10 each) were fed a 0.5% cholesterol diet for 12 weeks. One group served as a control and was sacrificed at the end of 12 weeks. Seven other groups were shifted to a normal diet and received a drug(s) or placebo for the second 12 weeks. The high dose of etidronate (3 mg/kg/day) with lovastatin (6 mg/kg/day) significantly reduced the percent of aortic atherosclerotic lesions [56 ± 21 vs. 77 ± 17% (mean ± SD), p < 0.05] in the regression study. Compared to the control groups for etidronate and lovastatin, the high or low dose (0.15 mg/kg/day) of etidronate significantly reduced aortic standardized plaque volume per unit (18.7 ± 7.9 or 18.8 ± 9.1 vs. 28.4 ± 11.8 mm·%, p < 0.05). Lovastatin reduced pulmonary artery maximum plaque thickness (0.13 ± 0.10 vs. 0.23 ± 0.11mm, p < 0.05). There were no differences in serum lipid and calcium levels in the control and treated groups. The high dose of etidronate inhibited bone mineralization as expected, whereas the low dose of etidronate did not. These data suggest that etidronate with lovastatin can regress aortic atherosclerosis in the cholesterol-fed rabbit placed on a normal diet.

          Related collections

          Author and article information

          S. Karger AG
          18 November 2008
          : 85
          : 6
          : 370-377
          Cardiovascular Division, Department of Medicine, and Cardiovascular Research Institute, University of California, San Francisco, Calif., and Procter & Gamble Pharmaceuticals, Norwich, N.Y., USA
          176738 Cardiology 1994;85:370–377
          © 1994 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          : 21 May 1994
          : 03 June 1994
          Page count
          Pages: 8
          General Cardiology, Basic Research

          General medicine,Neurology,Cardiovascular Medicine,Internal medicine,Nephrology
          Etidronate,Cholesterol-fed rabbit,Lovastatin,Plaque thickness,Atherosclerosis


          Comment on this article